LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Can you take Jardiance with Rybelsus? Yes, these two type 2 diabetes medications can be safely combined under medical supervision. Jardiance (empagliflozin), an SGLT2 inhibitor, and Rybelsus (semaglutide), a GLP-1 receptor agonist, work through different mechanisms to control blood glucose levels. Because they target distinct pathways—Jardiance acting on the kidneys and Rybelsus affecting the pancreas, liver, gut, and brain—their combined use can provide complementary benefits for glycaemic control and weight management. Many patients with type 2 diabetes require multiple medications to achieve optimal HbA1c targets, and this combination represents an evidence-based approach aligned with NICE guidance. However, combining diabetes medications requires careful monitoring and should only be undertaken with appropriate medical guidance to ensure safety and effectiveness.
Quick Answer: Jardiance and Rybelsus can be safely taken together under medical supervision as they work through different mechanisms to control blood glucose in type 2 diabetes.
Yes, Jardiance (empagliflozin) and Rybelsus (semaglutide) can be taken together under appropriate medical supervision. These two medications work through different mechanisms to control blood glucose levels in type 2 diabetes, and there is no known pharmacological interaction that prevents their combined use. Many patients with type 2 diabetes require multiple medications to achieve optimal glycaemic control, and this combination represents a complementary approach to diabetes management.
Jardiance belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, whilst Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist. Because they target different pathways in glucose regulation, combining them can provide additive benefits for blood sugar control and weight management. Jardiance has demonstrated cardiovascular benefits in clinical trials, reducing the risk of heart failure hospitalisation and cardiovascular death in people with type 2 diabetes. Oral semaglutide (Rybelsus) has shown cardiovascular safety but has not demonstrated cardiovascular superiority in outcomes trials.
The National Institute for Health and Care Excellence (NICE) guidance for type 2 diabetes (NG28) allows for combination therapy when monotherapy fails to achieve treatment targets, though specific eligibility criteria must be met for each medication class. It's important to note that neither medication is indicated for type 1 diabetes.
Self-adjusting or combining diabetes medications without medical guidance can be dangerous and may lead to complications such as hypoglycaemia or other adverse effects. Your healthcare team will provide personalised advice on dosing, timing, and monitoring requirements to ensure safe and effective treatment. If you are pregnant, breastfeeding, or planning pregnancy, special considerations apply, as these medications are generally not recommended during pregnancy or breastfeeding.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Understanding how these medications work helps explain why they can be used together effectively. Jardiance (empagliflozin) works by blocking SGLT2 proteins in the kidneys, which normally reabsorb glucose from urine back into the bloodstream. By inhibiting this process, Jardiance causes excess glucose to be excreted in the urine, thereby lowering blood sugar levels independently of insulin. This mechanism also results in modest weight loss and a mild diuretic effect, which can contribute to blood pressure reduction. Importantly, Jardiance has demonstrated cardiovascular benefits in clinical trials, reducing the risk of heart failure hospitalisation and cardiovascular death in people with type 2 diabetes.
Rybelsus (semaglutide) is the first oral GLP-1 receptor agonist available in the UK. It mimics the action of the naturally occurring hormone GLP-1, which is released after eating. Semaglutide works by:
Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner (meaning it only works when blood sugar is elevated)
Suppressing glucagon release, which reduces glucose production by the liver
Slowing gastric emptying, which helps control post-meal blood sugar spikes
Reducing appetite through effects on brain centres that regulate hunger, often leading to significant weight loss
Because Jardiance works primarily through the kidneys and Rybelsus through multiple mechanisms involving the pancreas, liver, gut, and brain, their combined effects can provide comprehensive glucose control. Neither medication typically causes hypoglycaemia when used alone or together (unless combined with insulin or sulphonylureas), as their glucose-lowering effects are largely glucose-dependent or insulin-independent.
It's worth noting that GLP-1 receptor agonists like Rybelsus should not be used in combination with DPP-4 inhibitors (e.g., sitagliptin, linagliptin), as both affect the same pathway and provide limited additional benefit when used together.
Whilst Jardiance and Rybelsus can be safely combined, there are important safety considerations to be aware of. Gastrointestinal side effects are common with Rybelsus, particularly when starting treatment or increasing the dose. These include nausea, vomiting, diarrhoea, and abdominal discomfort. When combined with Jardiance, which increases urination, there is a theoretical risk of dehydration if gastrointestinal symptoms are severe. It is essential to maintain adequate fluid intake and contact your GP if you experience persistent vomiting or diarrhoea.
Kidney function monitoring is particularly important when taking Jardiance. SGLT2 inhibitors can cause a small, temporary reduction in estimated glomerular filtration rate (eGFR) when first started. While Jardiance is typically not recommended for people with severely impaired kidney function (eGFR below 20 mL/min/1.73m²), it's important to note that the glucose-lowering effect diminishes at lower eGFR levels, even though cardiovascular and renal benefits may persist. Your healthcare team should check your kidney function before starting Jardiance and periodically thereafter. Rybelsus is generally safe for people with mild to moderate kidney impairment, though caution is advised in severe renal disease.
Diabetic ketoacidosis (DKA) is a rare but serious complication associated with SGLT2 inhibitors, including Jardiance. Euglycaemic DKA (where blood glucose may not be extremely elevated) can occur, particularly during illness, surgery, or significant dietary restriction. UK guidance recommends temporarily stopping SGLT2 inhibitors during acute illness, dehydration, or before major surgery (typically at least 3 days before). Warning signs of DKA include:
Excessive thirst and urination
Nausea and vomiting
Abdominal pain
Unusual fatigue
Difficulty breathing
Confusion
Seek immediate medical attention if you experience these symptoms. Consider blood ketone testing if you feel unwell while taking an SGLT2 inhibitor, even if your blood glucose is not very high.
Additional risks include genital and urinary tract infections with Jardiance due to increased glucose in the urine. Rybelsus may increase the risk of pancreatitis (stop taking and seek urgent medical care if you develop severe, persistent abdominal pain), gallbladder disease, and may worsen diabetic retinopathy in some patients, particularly those with pre-existing retinopathy. Fournier's gangrene, a rare but serious infection of the genitals and perineum, has been reported with SGLT2 inhibitors; seek urgent medical attention for pain, tenderness, redness, or swelling in the genital/perineal area accompanied by fever.
Very low-carbohydrate or ketogenic diets should be approached with caution when taking SGLT2 inhibitors due to increased DKA risk.
Before starting or combining Jardiance and Rybelsus, have a comprehensive discussion with your healthcare provider about several key topics. Your complete medical history is essential, particularly any history of kidney disease, heart failure, recurrent urinary or genital infections, pancreatitis, gastroparesis (delayed stomach emptying), or thyroid problems. Animal studies with semaglutide have shown thyroid C-cell tumours, though the human relevance of this finding is unknown. Discuss any personal or family history of thyroid conditions with your healthcare provider.
Current medications must be reviewed, as both drugs can interact with other treatments. Rybelsus absorption can be affected by other oral medications, and it must be taken on an empty stomach with a small amount of water (up to 120 mL), waiting at least 30 minutes before eating, drinking, or taking other medications. The tablet should be swallowed whole and not split, crushed, or chewed. Jardiance may enhance the blood pressure-lowering effects of antihypertensive medications, potentially requiring dose adjustments. If you take insulin or sulphonylureas, your doses may need to be reduced when adding these medications to prevent hypoglycaemia.
If you are taking warfarin, more frequent INR monitoring may be needed when starting semaglutide. Similarly, if you take levothyroxine, thyroid function should be monitored when initiating semaglutide. Remember that GLP-1 receptor agonists like Rybelsus should not be combined with DPP-4 inhibitors.
Pregnancy and family planning are important considerations. Neither medication is recommended during pregnancy or breastfeeding. If you're planning pregnancy, semaglutide should be discontinued at least 2 months before a planned conception due to its long half-life.
Treatment goals and expectations should be clearly established. Discuss:
Your target HbA1c level and how these medications will help achieve it
Expected weight loss and timeframe
Cardiovascular benefits, particularly if you have established heart disease
Cost considerations, as both medications can be expensive
How long you might need to take these medications
What constitutes treatment success or failure
Your healthcare provider should also explain the monitoring schedule, including how often you'll need blood tests to check HbA1c, kidney function, and other parameters, as well as when to schedule follow-up appointments to assess treatment response and tolerability.
Effective monitoring and proactive side effect management are crucial when taking Jardiance and Rybelsus together. Regular blood tests are essential, typically including HbA1c every 3-6 months once stable, kidney function (eGFR and creatinine) at baseline and periodically thereafter, and liver function tests if clinically indicated. For those with chronic kidney disease, urine albumin-to-creatinine ratio (ACR) should also be monitored. Your GP may also monitor electrolytes, particularly if you experience gastrointestinal symptoms or take diuretics.
Managing Rybelsus-related gastrointestinal symptoms is often the primary challenge when starting this combination. To minimise nausea and other digestive issues:
Start with the lowest dose (3 mg) and increase gradually as prescribed
Eat smaller, more frequent meals rather than large portions
Avoid high-fat, greasy, or spicy foods that may worsen symptoms
Stay well-hydrated, particularly if experiencing vomiting or diarrhoea (if you have heart failure or are on fluid restriction, follow your clinician's specific guidance)
Take the medication consistently at the same time each morning
Allow symptoms to settle before dose escalation (usually 4 weeks minimum)
Most gastrointestinal side effects improve within 4-8 weeks as your body adjusts to the medication.
For Jardiance-related issues, maintain good genital hygiene to reduce infection risk, stay well-hydrated (aim for 6-8 glasses of water daily unless on fluid restriction), and monitor for signs of urinary tract infections such as burning during urination, increased frequency, or cloudy urine. During periods of acute illness, follow UK 'sick day rules' by temporarily stopping your SGLT2 inhibitor until you're eating and drinking normally again. Consider having ketone testing supplies available if you take an SGLT2 inhibitor.
Contact your GP promptly if you develop:
Signs of genital infection (itching, discharge, redness)
Symptoms suggesting urinary tract infection
Persistent nausea, vomiting, or abdominal pain
Unusual fatigue or difficulty breathing
Significant unintended weight loss
Symptoms of dehydration (dizziness, reduced urine output, dark urine)
Visual changes (particularly if you have pre-existing diabetic retinopathy)
Right upper abdominal pain, fever or jaundice (possible gallbladder issues)
Pain, tenderness, redness or swelling in the genital or perineal area
Blood glucose monitoring frequency should be discussed with your diabetes team. Whilst these medications rarely cause hypoglycaemia alone, monitoring helps assess treatment effectiveness and can identify any unexpected patterns. Keep a record of any side effects and bring this to your appointments to help your healthcare team optimise your treatment plan.
If you experience any suspected adverse reactions to these medications, you can report them through the MHRA Yellow Card Scheme (website: yellowcard.mhra.gov.uk or search 'MHRA Yellow Card' in your app store).
No, there is no known pharmacological interaction between Jardiance and Rybelsus. They work through different mechanisms—Jardiance through the kidneys and Rybelsus through multiple pathways including the pancreas and gut—making them complementary rather than conflicting in their actions.
Common side effects include gastrointestinal symptoms (nausea, vomiting, diarrhoea) from Rybelsus and increased urination with potential genital or urinary tract infections from Jardiance. Maintaining adequate hydration is important, and rare but serious risks include diabetic ketoacidosis and pancreatitis.
Rybelsus must be taken on an empty stomach with up to 120 mL of water, waiting at least 30 minutes before eating, drinking, or taking other medications including Jardiance. The tablet should be swallowed whole and not split, crushed, or chewed.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
